Int. Journal of Clinical Pharmacology and Therapeutics, Volume 61 (2023) - November (515 - 519)

Prevention of pneumocystis pneumonia in patients with hematological diseases: Efficacy of low-dose atovaquone

Tomiyuki Sugi1, 2, Mitsuo Mita1, Ryouta Kushi2, Homare Hanai2, Tomoyuki Uchida3, Morihiro Inoue3, Masao Hagihara3
1 Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, 2 Department of Pharmacy, and 3 Department of Hematology, Eiju General Hospital, Tokyo, Japan

Add to Cart  

 

DOI 10.5414/CP204368

Abstract

Objective: At our institution, patients with hematological disease who require Pneumocystis jirovecii pneumonia (PJP) prophylaxis were administered atovaquone at a low dose (750 mg/day). However, there have been few reports on the efficacy of low-dose atovaquone administration, and the purpose of this study is, therefore, to investigate its effectiveness.
Materials and methods: We investigated the expression of PJP in patients with hematological disease who received atovaquone administration. Atovaquone was administered at a low dose of 750 mg once daily, and the follow-up time was the period of PJP prophylaxis that included atovaquone administration.
Results: 85 patients were included in the study. The median age of the study population was 72 years (range: 33 – 97). The duration of atovaquone treatment and follow-up time were 150 days (22 – 1,018) and 258 days (22 – 1,457), respectively. In hematologic diseases, multiple myeloma was high in 31 patients and malignant lymphoma in 28 patients. No patients exhibited PJP during the observation period.
Conclusion: In hematological disease patients with relatively low risk of PJP, low-dose atovaquone may prevent the onset of PJP.

Author Details

Authors

Departments

  • 1 Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University,
  • 2 Department of Pharmacy, and
  • 3 Department of Hematology, Eiju General Hospital, Tokyo, Japan

Address

Tomiyuki Sugi
Department of Cardiovascular Pharmacology
Education and Research Unit for Comprehensive Clinical Pharmacy
Meiji Pharmaceutical University
2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan
Email: [email protected]

Log in for Subscribers

Citation

Tomiyuki Sugi, Mitsuo Mita, Ryouta Kushi, Homare Hanai, Tomoyuki Uchida, Morihiro Inoue, Masao Hagihara. Prevention of pneumocystis pneumonia in patients with hematological diseases: Efficacy of low-dose atovaquone
. Int J Clin Pharmacol Ther. 2023; 61: 515-519. doi: 10.5414/CP204368. Pubmed: https://pubmed.ncbi.nlm.nih.gov/37622674/; PMID: 37622674.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart